Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Oncolytics Biotech Research Collaboration with Coherus Oncology, Inc.
Oncolytics Biotech entered into a clinical supply agreement with Coherus Oncology to evaluate pelareorep in combination with LOQTORZI (toripalimab-tpzi) for the treatment of squamous cell anal carcinoma (SCAC). The clinical study, expected to begin in Q1 2027, will target second-line patients who have progressed on standard-of-care treatments.
Eton Pharmaceuticals Research Collaboration with Baylor College of Medicine
Eton Pharmaceuticals has entered into a license and development agreement with Baylor College of Medicine to evaluate mecasermin (ET-900) for the treatment of infantile and epileptic spasms. The partnership includes an investigator-sponsored Phase 2 clinical study with patient dosing targeted for Q1 2027, following the submission of an Investigational New Drug application to the FDA.
Vir Biotechnology Research Collaboration with Gilead Sciences, Inc. Worth $1.88B
Vir Biotechnology and Gilead Sciences have entered into a global strategic collaboration to discover and engineer three novel PRO-XTEN dual-masked T-cell engager (TCE) development candidates for solid tumors. Vir receives $90 million in upfront consideration (including a $25 million equity investment at a 30% premium) and is eligible for up to $1.785 billion in total potential milestones plus royalties.
Regeneron Pharmaceuticals Research Collaboration with Sanofi Worth $1B
Regeneron and Sanofi entered into a Sixth Amendment to their existing Antibody LCA to co-develop and co-commercialize four new long-acting antibodies targeting IL-13, IL-4, and IL-4Rα. Sanofi will pay Regeneron an upfront payment of $1.0 billion and up to $7.0 billion in potential development, regulatory, and commercial milestones, with global profits and development costs shared equally.
Tempest Therapeutics Research Collaboration with Factor Bioscience Inc. Worth $5M
Tempest Therapeutics entered into a Master Services Agreement and a specific work order with Factor Bioscience Inc. to develop in vivo CAR-T therapies. The agreement involves an estimated $5.0 million in annual fees and is considered a related-party transaction as Tempest's CEO, Dr. Matt Angel, is the majority owner and CEO of Factor Bioscience.
Deep Fission Research Collaboration with Youngquist Brothers, LLC
Deep Fission has entered into a collaboration with Youngquist Brothers to evaluate and test drilling and borehole-construction methods for its underground nuclear reactor deployment model. The partnership leverages Youngquist's expertise in large-diameter drilling to support Deep Fission's strategy of placing small modular reactors one mile underground. The companies recently completed a successful equipment demonstration in Florida involving a 30-inch prototype reactor canister.
Beeline Holdings Research Collaboration with Loft 100 Studios
Beeline Holdings has partnered with Emmy Award-winning Loft 100 Studios to produce a "Bizumentary" exploring the mortgage and housing crisis. The 45-minute production will examine industry challenges and innovative lending solutions, with an expected initial distribution reaching up to 90 million viewers via BizTV and other networks.
Tempest Therapeutics Research Collaboration with Heibei Senlang Biotechnology Co., Ltd.
Tempest Therapeutics entered into an exclusive collaboration and option agreement with Heibei Senlang Biotechnology to develop and commercialize an in vivo CAR-T technology platform worldwide, excluding Greater China. Tempest paid an option fee of approximately $0.447 million for a four-month window to license the technology, which includes a Phase 1 dual-targeting candidate for multiple myeloma. The deal establishes Tempest as a multi-platform in vivo CAR-T company, combining Senlang's lentiviral vector platform with Tempest's existing LNP delivery technology.
Co-Diagnostics Research Collaboration with ReadyGo Diagnostics Ltd.
Co-Diagnostics and ReadyGo Diagnostics are collaborating to evaluate the integration of ReadyGo's GoCollect sample-preparation technology with the Co-Dx PCR platform. The initial focus is on decentralized Ebola virus detection, with the goal of expanding the platform's capabilities to blood-based molecular testing for pathogens like HIV and hepatitis B and C.
Co-Diagnostics Research Collaboration with ReadyGo Diagnostics Ltd
Co-Diagnostics entered into a material transfer agreement with ReadyGo Diagnostics Ltd to evaluate the compatibility of ReadyGo's sample collection and preparation technologies with the Co-Dx PCR platform. The collaboration involves feasibility studies and compatibility testing to potentially streamline the sample-to-result workflow for decentralized and point-of-care testing. The agreement is preliminary and does not obligate either party to enter into a formal commercial or development arrangement.
Perspective Therapeutics Research Collaboration with Merck
Perspective Therapeutics has entered into a clinical trial collaboration and supply agreement with Merck to evaluate its targeted alpha-particle therapy [212Pb]PSV359 in combination with Keytruda. The combination will be tested in an ongoing Phase 1/2a study for FAP-alpha positive solid tumors, with Perspective sponsoring the study and Merck providing pembrolizumab at no cost.